Menu
Not yet recruiting NCT07233785

Comparison of ACB With ACB and BiFeS Combination in Knee Arthroplasty Surgeries

No phase Interventional Postoperative Pain Management Knee Surgery Knee Arthroplasty, Total

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Adductor Canal Block (ACB) Only, Adductor Canal Block (ACB) + Biceps Femoris Short Head Block (BiFeS).
Who it may be relevant to
Registry conditions: Postoperative Pain Management, Knee Surgery, Knee Arthroplasty, Total. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparison of the Postoperative Analgesic Efficacy of the Combination of Adductor Canal Block and Biceps Femoris Short Head Block Versus Adductor Canal Block Alone in Patients Undergoing Total Knee Arthroplasty

Overview

The aim is to compare the postoperative analgesic effects of Adductor Canal and Biceps Femoris Short Head Blocks with Adductor Canal Block in patients undergoing Knee Arthroplasty surgery

Detailed description

Patients were divided into two randomized groups: Group 1 (ACB group, n=30) and Group 2 (ACB+BiFeS group, n=30). All patients will receive the same standard spinal anesthesia per hospital protocol. All blocks will be applied with the same ultrasonography and block equipment, and by the same physician. After the surgery, patients in Group 1 will receive Adductor Canal Block (ACB) with 20 mL of 0.25% bupivacaine. Patients in Group 2 will receive Adductor Canal Block with 20 mL of 0.25% bupivacaine and Biceps Femoris Short Head (BiFeS) with 20 mL of 0.25% bupivacaine. Routine analgesic procedure consisting of 3x400mg Ibuprofen will be followed postoperatively for 24 hours. Numeric Rating Scale (NRS) will be used to assess postoperative pain on 1st, 6th, 12th, 18th and 24th hours after the surgery. Tramadol 1mg/kg IV will be administered as a rescue analgesic for all patients if NRS score is higher than 4. Total Tramadol consumption will be calculated.

Interventions

  • Procedure Adductor Canal Block (ACB) Only
    20 mL of 0.25% bupivacaine
  • Procedure Adductor Canal Block (ACB) + Biceps Femoris Short Head Block (BiFeS)
    20 mL of 0.25% bupivacaine

Primary outcome measures

  • 1. Numeric Rating Scale (NRS) Scores [Time frame: Postoperative 24 hours]
Secondary outcome measures (1)
  • Total tramadol consumption [Time frame: Postoperative 24 hours]

Eligibility criteria

Inclusion criteria

  • Adult patients over 18 years of age who underwent percutaneous nephrolithotomy under general anesthesia and were I-II-III according to the American Society of Anesthesiologists (ASA) risk classification were included in the study.

Exclusion criteria

  • patients who did not give consent,
  • patients with coagulopathy,
  • patients with signs of infection at the block application site,
  • patients using anticoagulants,
  • patients with known allergies to any of the study drugs,
  • patients with unstable hemodynamics,
  • patients who could not cooperate during postoperative pain assessment
  • patients who wanted to withdraw from the study,
  • patients with alcohol and drug addiction,
  • patients with musculoskeletal abnormalitie

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Other

Study locations

Turkey (Türkiye) · 1 center
  • Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation — Sivas

Identifiers

NCT: NCT07233785 · 2025-09/52

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗